Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

Background & Aims In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as
a “role model” for precision oncology in gastrointestinal cancers. However, its rarity, paired …

Simple Summary Despite the continuous development of treatment technology,
glioblastoma remains a challenge for modern medicine. The standard of care remains a …

Cutaneous melanoma is an aggressive tumor responsible for 90% of mortality related to skin
cancer. In the recent years, the discovery of driving mutations in melanoma has led to better …

The RAS-regulated RAF–MEK1/2–ERK1/2 pathway promotes cell proliferation and survival
and RAS and BRAF proteins are commonly mutated in cancer. This has fuelled the …

Melanoma is the less common but the most malignant skin cancer. Since the survival rate of
melanoma metastasis is about 10–15%, many different studies have been carried out in …

IDH-wild type (wt) glioblastoma (GB) accounts for approximately 90% of all GB and has a
poor outcome. Surgery and adjuvant therapy with temozolomide and radiotherapy is the …

Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer
(NSCLC) cases, identifying a relevant subset of patients that need to be promptly managed …

Melanoma, a highly aggressive form of skin cancer, poses a significant global health
burden, with 331,647 new cases and 58,645 deaths reported in 2022. The development of …